Delayed Emergence of HIV-1 Variants Resistant to 4′-Ethy Nyl-2-Fluoro-2′-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine,Tenofovir,Emtricitabine and BMS-986001

Mitsuya H. , Weinhold K.J. , Furman P.A. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985; 82: 7096–7100.

De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 33: 307–320.

Maeda K. , Das D. , Mitsuya H. Development of antiviral therapeutics for HIV-1 infection and AIDS. In Hall J.C. , Hall B.J. , Cockerell C.J. (Editors). HIV/AIDS in the post-HAART era: manifestations, treatment & epidemiology. Shelton, CT: People's Medical Publishing House 2011; pp. 900–937.

Tsibris A.M. , Hirsch M.S. Antiretroviral therapy in the clinic. J Virol 2010; 84: 5458–5464.

Chun T.W. , Fauci A.S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012; 26: 1261–1268.

Richman D.D. , Margolis D.M. , Delaney M. The challenge of finding a cure for HIV infection. Science 2009; 323: 1304–1307.

Tang M.W. , Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012; 72: e1–e25.

Menéndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 2013; 98: 93–120.

Fernandez-Fernandez B. , Montoya-Ferrer A. , Sanz A.B. Tenofovir nephrotoxicity: 2011 update. Aids Res Treat 2011; 2011: 354908.

Malik A. , Abraham P. , Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment – case report and review of literature. J Infect 2005; 51: E61–E65.

Powderly W.G. Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep 2012; 9: 218–222.

Miller M.D. K65R, TAMs and tenofovir. AIDS Rev 2004; 6: 22–33.

Brenner B.G. , Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 2009; 3: 583–594.

Kawamoto A. , Kodama E. , Sarafanos S.G. 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol 2008; 40: 2410–2420.

Kodama E.I. , Kohgo S. , Kitano K. 4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001; 45: 1539–1546.

Nakata H. , Amano M. , Koh Y. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother 2007; 51: 2701–2708.

Murphey-Corb M. , Rajakumar P. , Michael H. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother 2012; 56: 4707–4712.

Tamiya S. , Mardy S. , Kavlick M.F. , Yoshimura K. , Mitsuya H. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 2004; 78: 12030–12040.

Yoshimura K. , Kato R. , Yusa K. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A 1999; 96: 8675–8680.

Ohrui H. 2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec 2006; 6: 133–143.

Nitanda T. , Wang X. , Kumamoto H. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob Agents Chemother 2005; 49: 3355–3360.

Koh Y. , Amano M. , Towata T. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol 2010; 84: 11961–11969.

Maeda K. , Yoshimura K. , Shibayama S. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001; 276: 35194–35200.

Aoki M. , Danish M.L. , Aoki-Ogata H. The loss of protease dimerization inhibition activity of tipranavir (TPV) and its association with HIV-1 acquisition of resistance to TPV. J Virol 2012; 86: 13384–13396.

Moutouh L. , Corbeil J. , Richman D.D. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A 1996; 93: 6106–6111.

Yusa K. , Kavlick M.F. , Kosalaraksa P. , Mitsuya H. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. Antiviral Res 1997; 36: 179–189.

Michailidis E. , Marchand B. , Kodama E.N. Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem 2009; 284: 35681–35691.

Hattori S. , Ide K. , Nakata H. Potent activity of a nucleoside reverse transcriptase inhibitor, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother 2009; 53: 3887–3893.

Lauring A.S. , Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 2010; 6: e1001005.

De Meyer S. , Azijn H. , Surleraux D. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314–2321.

Poveda E. , de Mendoza C. , Martin-Carbonero L. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007; 60: 885–888.

Imamichi T. , Sinha T. , Imamichi H. High-level resistance to 3′-azido-3′-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol 2000; 74: 1023–1028.

Imamichi T. , Berg S.C. , Imamichi H. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-to-Gly) at codon 69. J Virol 2000; 74: 10958–10964.

Imamichi T. , Murphy M.A. , Imamichi H. , Lane H.C. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistant profiles. J Virol 2001; 75: 3988–3992.

Kisic M. , Matamoros T. , Nevot M. Thymidine analogue excision and discrimination modulated by mutational complexes including single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase. J Biol Chem 2011; 286: 20615–20624.